A Clinical Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of TQB3217 Tablets in Subjects With Advanced Malignant Tumors

Phase 1 Not yet recruiting 40 enrolled Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

NaSingle-groupOpen-labelTreatment

Summary

This is the first-in-human clinical study of TQB3217, aiming to evaluate the safety, tolerability, and pharmacokinetic characteristics of TQB3217 in advanced solid tumors, and to preliminarily explore its efficacy in solid tumors.

Timeline

Start: 2025-12
Primary completion: 2026-12
Completion: 2026-12

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	TQB3217	Unknown	—	Oral

Indications

No indication recorded.